Field Guide
Top Oncology Journals
Journals for cancer research, trials, and oncology practice. This guide covers 9 journals with impact factors, acceptance rates, review timelines, and open access costs - everything you need to choose the right venue for your research.
Journal Comparison Table
| Journal | Tier | Impact Factor | Acceptance Rate | Review Time | Open Access |
|---|---|---|---|---|---|
| Annals of Oncology Ann. Oncol. | Top Tier | 80.4 | ~10-20% | ~90-120 days median | See details |
| Cancer Cell | Top Tier | 56.1 | ~8-10% | ~5 days to desk decision; ~8 weeks to first decision after review | See details |
| Journal of Clinical Oncology J. Clin. Oncology | Top Tier | 44.7 | ~15% | ~30 days | See details |
| The Lancet Oncology Lancet Oncology | Top Tier | 33.7 | ~8% | ~14 days (very fast) | See details |
| Nature Reviews Cancer Nat. Rev. Cancer | Strong Option | 60.7 | ~2-5% (highly selective, mostly invited) | ~60-90 days median | See details |
| JAMA Oncology | Strong Option | 23.9 | ~8% | ~21 days | See details |
| Cancer Research Cancer Res. | Strong Option | 22.6 | Not publicly reported | Varies by manuscript | See details |
| Clinical Cancer Research Clin. Cancer Res. | Strong Option | 10.9 | ~20-30% | ~100-130 days median | See details |
| Annals of Surgical Oncology Ann Surg Oncol | Strong Option | Not verified as a current 2025 JCR value | Not publicly disclosed | Not publicly verified | See details |
Found your target journal - now check if your manuscript is ready
Most desk rejections come down to scope and framing, not the science itself. Start with the Free Readiness Scan to check your manuscript against what oncology editors actually look for before you commit to a submission.
Start with the Free Readiness Scan. Unlock the Full Review from $39, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier.
Private API processing. Your manuscript is not used to train models.
Run my Free Readiness Scan →Understanding Journal Tiers
Tier 1 (Cancer Cell, Lancet Oncology, JCO): For novel therapeutic targets, practice-changing clinical trials, or major outcomes research. Cancer Cell emphasizes mechanism; Lancet Oncology and JCO emphasize clinical impact. Expect 8-16 weeks to first decision, 80%+ desk rejection at Cancer Cell.
Tier 2 (JAMA Oncology, Nature Reviews Cancer): JAMA Oncology for clinical oncology research that doesn't reach Lancet/JCO bar. Nature Reviews Cancer for reviews and broad conceptual advances - they commission most reviews, but exceptional unsolicited perspectives get considered.
Tier 3: For oncology-specific journals not listed above (e.g., Oncogene, Molecular Cancer Research, Cancer Research for basic work; Annals of Surgical Oncology for clinical). These are solid venues when Tier 1/2 aren't realistic.
Publishing in Oncology
Oncology publishing has a clear hierarchy, and understanding it is crucial for manuscript placement. The field breaks down into three tiers that serve different purposes. Cancer Cell is the top basic/translational oncology journal. If your work shows a novel mechanism of tumor development, drug resistance, or therapeutic target, this is where it needs to go. They publish about 150 papers per year - extremely selective. Lancet Oncology and JCO are the clinical giants. Lancet Oncology emphasizes trials with global health implications and practice-changing therapies. JCO (Journal of Clinical Oncology) is the most widely read clinical oncology journal - if you want practicing oncologists to read your work, this is the venue. JCO publishes more papers than Lancet Oncology but maintains comparable impact. JAMA Oncology has grown rapidly since its 2015 launch and now rivals JCO in prestige for clinical oncology research. It offers faster timelines than the traditional giants. The key insight: match your study type to the journal. Basic mechanism work goes to Cancer Cell. Clinical trials and outcomes research go to Lancet Oncology or JCO. Health services research in oncology fits JAMA Oncology. Many strong papers get rejected not for quality but for wrong fit.
Guidance by Career Stage
🎓 Graduate Students
Grad students in oncology face a bottleneck. You're unlikely to get Cancer Cell or Lancet Oncology as first author without exceptional data. Target JCO Precision Oncology (sister journal) or present at ASCO first. Your goal is establishing credibility through solid clinical research at a reasonable journal.
🔬 Postdocs
Postdocs with strong translational data - particularly on novel biomarkers or therapeutic combinations - should aim for Cancer Cell. Postdocs with clinical trial data should aim for JAMA Oncology or JCO. If your PI has a track record at these journals, leverage it. If not, build credibility at a lower tier first.
👨🔬 Principal Investigators
PIs in oncology benefit from the field's publication volume. Consider which journal your target audience reads - practicing oncologists read JCO, researchers read Cancer Cell. Tier 1 oncology journals are realistic targets if you have strong data and a clear narrative about clinical significance.
⏱️ Review Timelines
Cancer Cell: typically 6-10 weeks to first decision. Lancet Oncology: 8-12 weeks. JCO: 4-8 weeks for initial assessment, faster forLetters. JAMA Oncology: 4-8 weeks. Nature Reviews Cancer: Invitation-only for reviews; unsolicited submissions are rare.
🔓 Open Access & Costs
Cancer Cell is subscription-only (Cell Press). Lancet Oncology and JCO offer open access for ~£3,500-4,500/$4,000-5,000. JAMA Oncology offers open access for $3,000. Nature Reviews Cancer charges ~$11,000 for open access.
Common Mistakes to Avoid
- ✕Submitting clinical trial results to Cancer Cell - wrong venue, they want mechanism
- ✕Not citing recent Lancet Oncology papers - editors notice if you miss key references
- ✕Underestimating the importance of clinical significance framing
- ✕Not having a statistical review before submission - oncology journals are particularly rigorous
Frequently Asked Questions
Which oncology journal has the highest impact factor?
Cancer Cell has the highest IF at 44.5. However, Lancet Oncology (35.9) and JCO (41.9) are considered equally prestigious in clinical oncology. Impact factor varies by citation patterns - review articles cite more, which inflates IF.
What's the difference between Cancer Cell and JCO?
Cancer Cell focuses on basic and translational oncology - molecular mechanisms, novel targets, drug discovery. JCO focuses on clinical oncology - trials, outcomes, guidelines. They're not interchangeable; fit matters more than impact factor.
Can I publish clinical trial results in Cancer Cell?
No - Cancer Cell explicitly states they want 'fundamental discoveries in the fields of cancer biology.' Clinical trials with mechanistic correlates might fit, but pure clinical work should go to Lancet Oncology or JCO.
Detailed Journal Guides
Latest Journal-Specific Guides in This Field
More Guides in This Field
Related Resources
Ready to submit? Check your manuscript first.
Start with the Free Readiness Scan to review your scope, significance framing, methods, and literature coverage against oncology journal standards before you submit.
Start with the Free Readiness Scan. Unlock the Full Review from $39, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier.
Private API processing. Your manuscript is not used to train models.
Run my Free Readiness Scan →